# Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia

> **NCT04445272** · PHASE2 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 495 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04445272
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-22
- **Primary completion:** 2020-12-23
- **Final completion:** 2020-12-23
- **Target enrollment:** 495 (ACTUAL)
- **Last updated:** 2021-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445272, "Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04445272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*